Medicine & pharma · Official intelligence
EMA recommends approval for Baxfendy (baxdrostat) for hypertension
The EMA's CHMP adopted a positive opinion on 12 November 2026 recommending marketing authorization for Baxfendy (baxdrostat), developed by AstraZeneca AB. This medication containing baxdrostat is indicated for treating adult patients with arterial hypertension. It introduces a novel mechanism for blood pressure management.
Original source
Read the source — ema.europa.eu ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.